Ropinirole can cause hair loss, but it’s uncommon. In clinical trials for both Parkinson’s disease and restless legs syndrome, hair loss (alopecia) was classified as an “infrequent” side effect, meaning it affected between 1 in 100 and 1 in 1,000 patients taking the drug. It’s not one of the more common side effects like nausea or drowsiness, but it is a recognized reaction listed in the official prescribing information.
What the Clinical Trials Show
The FDA-approved label for Requip (the brand name for ropinirole) lists alopecia as an infrequent adverse event observed during Phase 2 and Phase 3 clinical trials. This classification appeared in trials for both conditions the drug treats: Parkinson’s disease and restless legs syndrome. “Infrequent” in this context has a specific statistical meaning, placing hair loss in the range of 1 to 10 out of every 1,000 patients.
To put that in perspective, more common side effects of ropinirole like nausea, dizziness, and sleepiness affect anywhere from 10% to 40% of users depending on the dose. Hair loss is far less likely than any of those. But “infrequent” doesn’t mean “never,” and if you’re noticing thinning or shedding after starting ropinirole, the medication is a plausible explanation.
Why Dopamine Agonists May Affect Hair
Ropinirole belongs to a class of drugs called dopamine agonists, which mimic the effects of dopamine in the brain. It turns out dopamine doesn’t just act on the brain. Hair follicles are also sensitive to it. Lab research on human scalp hair follicles found that dopamine directly triggers follicles to enter their regression phase, the part of the hair cycle where growth stops and the follicle begins to shrink. Dopamine also reduced the rate at which hair matrix cells (the cells responsible for building the hair shaft) were dividing, and it decreased pigment production within the follicle.
In practical terms, this means a dopamine agonist like ropinirole could push more of your hair follicles into a resting state at the same time, leading to a type of diffuse shedding called telogen effluvium. This typically shows up as overall thinning rather than bald patches, and you might notice more hair falling out in the shower or on your pillow. The shedding usually doesn’t start immediately. Because of how the hair cycle works, it can take two to three months after starting or changing a dose before the effect becomes visible.
Hair Loss With Other Dopamine Agonists
Ropinirole isn’t the only dopamine agonist linked to hair loss. Reversible alopecia has been reported with bromocriptine, pergolide, and levodopa (a related dopamine-boosting drug). This pattern across the drug class supports the idea that the mechanism is related to dopamine’s effect on hair follicles rather than something unique to ropinirole’s chemical structure. If you’ve experienced hair loss on one dopamine agonist, switching to another in the same class may not resolve the problem.
Is the Hair Loss Reversible?
The reports of dopamine agonist-related hair loss in medical literature describe it as reversible, meaning hair typically regrows after the medication is stopped or the dose is reduced. This is consistent with telogen effluvium in general: because the follicles aren’t permanently damaged, they can re-enter the growth phase once the triggering factor is removed. Regrowth usually takes several months, since hair grows roughly half an inch per month and the follicle needs time to cycle back into active production.
If you’re taking ropinirole for Parkinson’s disease or restless legs syndrome and noticing hair thinning, it’s worth bringing it up at your next appointment. Hair loss can also be caused by nutritional deficiencies, thyroid problems, stress, or other medications, so your provider may want to rule those out before attributing it to ropinirole. Stopping or adjusting the medication is a decision that needs to weigh the hair loss against how well the drug is controlling your symptoms.